MDT

81.83

-0.81%↓

VEEV

209.89

-2.67%↓

A

100.29

-2.02%↓

WBA

10.86

-0.18%↓

CHE

562.75

-2.9%↓

MDT

81.83

-0.81%↓

VEEV

209.89

-2.67%↓

A

100.29

-2.02%↓

WBA

10.86

-0.18%↓

CHE

562.75

-2.9%↓

MDT

81.83

-0.81%↓

VEEV

209.89

-2.67%↓

A

100.29

-2.02%↓

WBA

10.86

-0.18%↓

CHE

562.75

-2.9%↓

MDT

81.83

-0.81%↓

VEEV

209.89

-2.67%↓

A

100.29

-2.02%↓

WBA

10.86

-0.18%↓

CHE

562.75

-2.9%↓

MDT

81.83

-0.81%↓

VEEV

209.89

-2.67%↓

A

100.29

-2.02%↓

WBA

10.86

-0.18%↓

CHE

562.75

-2.9%↓

Search

Arcutis Biotherapeutics Inc

Fechado

SetorSaúde

13.51 3.29

Visão Geral

Variação de preço das ações

24h

Atual

Mín

12.87

Máximo

13.08

Indicadores-chave

By Trading Economics

Rendimento

31M

-11M

Vendas

27M

71M

EPS

-0.09

Margem de lucro

-15.118

Funcionários

342

EBITDA

29M

-4.5M

Recomendações

By TipRanks

Recomendações

Compra Forte

Previsão para 12 meses

+46.04% upside

Dividendos

By Dow Jones

Próximos Ganhos

6 de mai. de 2025

Estatísticas de Mercado

By TradingEconomics

Capitalização de Mercado

85M

1.5B

Abertura anterior

10.22

Fecho anterior

13.51

Sentimento de Notícias

By Acuity

50%

50%

144 / 385 Ranking em Healthcare

Pontuação Técnica

By Trading Central

Confiança

Strong Bullish Evidence

Arcutis Biotherapeutics Inc Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

19 de abr. de 2025, 01:45 UTC

Ganhos

Preview -- Barron's

18 de abr. de 2025, 15:57 UTC

Grandes Movimentos do Mercado

Eli Lilly CEO Ricks Warns Against Unintentionally Raising Prices as Weight-Loss Pill Nears Market Launch

20 de abr. de 2025, 22:32 UTC

Principais Notícias

Stocks Poised for Lower Open -- Barrons.com

20 de abr. de 2025, 18:43 UTC

Principais Notícias

Chicago Fed's Goolsbee Has a Warning About Independence -- Barrons.com

20 de abr. de 2025, 18:00 UTC

Principais Notícias

Tesla, Alphabet, Verizon, Chipotle, IBM, Boeing, and Many More Stocks to Watch This Week -- Barrons.com

20 de abr. de 2025, 13:00 UTC

Principais Notícias

Airbus Promised a Green Aircraft. That Bet Is Now Unraveling. -- WSJ

20 de abr. de 2025, 06:00 UTC

Principais Notícias

Foreign Stocks Are Beating the U.S. Market. Here's How Much You Should Have in Your Portfolio. -- Barrons.com

20 de abr. de 2025, 03:00 UTC

Principais Notícias

Putin's War Economy Can't Escape Trump's Trade Blitz -- WSJ

20 de abr. de 2025, 02:00 UTC

Principais Notícias

Who Will Pay the Price for Trump's Economic Goals? -- WSJ

19 de abr. de 2025, 02:00 UTC

Principais Notícias

Tomatoes Become One of the First Everyday Casualties of Trade War -- WSJ

19 de abr. de 2025, 02:00 UTC

Principais Notícias

Beijing Stokes Patriotic Fervor and Blames U.S. for Trade War -- WSJ

18 de abr. de 2025, 20:42 UTC

Aquisições, Fusões, Aquisições de Empresas

What Bill Ackman Sees in Hertz and Why He's Betting Big on the Rental-Car Company -- Barrons.com

18 de abr. de 2025, 20:32 UTC

Principais Notícias

Trump to Replace Acting IRS Commissioner -- 2nd Update

18 de abr. de 2025, 20:15 UTC

Conversa de Mercado

Global Commodities Roundup: Market Talk

18 de abr. de 2025, 19:52 UTC

Conversa de Mercado

Correction to Aluminum Fee Rising Slower Than Forecast Article

18 de abr. de 2025, 19:40 UTC

Conversa de Mercado

Market Talk Roundup: Latest on U.S. Politics

18 de abr. de 2025, 19:40 UTC

Conversa de Mercado

Aluminum Fee Rising Slower Than Forecast From Tariff -- Market Talk

18 de abr. de 2025, 18:51 UTC

Ganhos

Netflix Has Made Several Risky Bets. Earnings Show They've Paid Off. -- Barrons.com

18 de abr. de 2025, 18:40 UTC

Aquisições, Fusões, Aquisições de Empresas

What Bill Ackman Sees in Hertz and Why He's Betting Big on the Rental-Car Company -- Barrons.com

18 de abr. de 2025, 18:29 UTC

Conversa de Mercado

Shorter Duration Seen as Way to Shield Portfolio From Political Turbulence -- Market Talk

18 de abr. de 2025, 18:21 UTC

Principais Notícias

Ford Halts Shipments of F-150s and Other Models to China -- WSJ

18 de abr. de 2025, 17:31 UTC

Principais Notícias

Trump to Replace Acting IRS Commissioner -- WSJ

18 de abr. de 2025, 17:24 UTC

Aquisições, Fusões, Aquisições de Empresas

Capital One's Discover Takeover Gets the Green Light. The Two Will Create the 6th-Largest U.S. Bank. -- Barrons.com

18 de abr. de 2025, 17:22 UTC

Aquisições, Fusões, Aquisições de Empresas

Capital One's $35 Billion Discover Takeover Clears Final Approvals -- Barrons.com

18 de abr. de 2025, 16:00 UTC

Principais Notícias

Trump's Trade War Threatens One of America's Top Energy Exports -- WSJ

18 de abr. de 2025, 15:53 UTC

Principais Notícias
Aquisições, Fusões, Aquisições de Empresas

Bill Ackman Teases Prospect of Uber, Hertz Partnership -- Update

18 de abr. de 2025, 15:46 UTC

Ganhos

Tech's Problems in China Are Getting Worse. These Companies Are Most at Risk. -- Barrons.com

18 de abr. de 2025, 15:10 UTC

Conversa de Mercado
Ganhos

Netflix Momentum Likely To Continue Thanks To Growing Subscriber Base -- Market Talk

18 de abr. de 2025, 14:46 UTC

Ganhos

Tech Earnings Have Good News for Chip Stocks, So Far. And 1 Warning. -- Barrons.com

18 de abr. de 2025, 14:24 UTC

Conversa de Mercado
Ganhos

Netflix Still Has Room to Add Subscribers -- Market Talk

Comparação entre Pares

Variação de preço

Arcutis Biotherapeutics Inc Previsão

Preço-alvo

By TipRanks

46.04% parte superior

Previsão para 12 meses

Média 19 USD  46.04%

Máximo 21 USD

Mínimo 15 USD

Com base em 8 analistas de Wall Street que oferecem metas de preço de 12 meses para Arcutis Biotherapeutics Inc - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Compra Forte

8 ratings

7

Comprar

1

Manter

0

Vender

Pontuação Técnica

By Trading Central

12.94 / 13.1134Suporte e Resistência

Curto Prazo

Strong Bullish Evidence

Médio Prazo

Very Strong Bearish Evidence

Longo Prazo

Bearish Evidence

Sentimento

By Acuity

144 / 385 Ranking em Saúde

Sentimento de Notícias

Neutral

Volatilidade

Abaixo da média

Volume de Notícias (RCV)

Abaixo da média

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

$

Sobre Arcutis Biotherapeutics Inc

Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing ARQ-154, a topical ZORYVE for the treatment of scalp and body psoriasis and seborrheic dermatitis; ARQ-252, a selective topical janus kinase type 1 inhibitor for hand eczema and vitiligo; ARQ-255, a topical JAK1 inhibitor for alopecia areata; and ARQ-234, a CD200R fusion protein for the treatment of moderate-to-severe atopic dermatitis. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California.